Minimally Invasive Thoracic Surgery Market by Procedure Type (Lung Resection Procedures, Esophageal Procedures, Mediastinal Procedures), Product Type (Surgical Systems, Surgical Instruments, Access Devices), Indication, End User - Global Forecast 2025-203
Description
The Minimally Invasive Thoracic Surgery Market was valued at USD 2.73 billion in 2024 and is projected to grow to USD 2.95 billion in 2025, with a CAGR of 8.30%, reaching USD 5.18 billion by 2032.
A forward-looking introduction that frames clinical evolution, stakeholder incentives, and the strategic convergence shaping minimally invasive thoracic surgery adoption
The evolution of thoracic surgery toward less invasive approaches has entered a stage where clinical promise and commercial momentum intersect. Advances in instrumentation, imaging, and robotic assistance have collectively shifted procedural paradigms, enabling surgeons to reduce patient trauma and expedite recovery while preserving or improving diagnostic and therapeutic effectiveness. This shift is not solely technical; it reflects a broad, multipronged transformation driven by payers, patients, and providers who increasingly prioritize outcomes, throughput, and predictable perioperative pathways.
Clinicians now operate within an ecosystem that demands interoperability between devices, streamlined disposable management, and consistent visualization quality. As a result, technology adoption decisions are informed by procedure type, device ergonomics, and institutional capacity to support next-generation tools. Meanwhile, health systems are recalibrating resource allocation to balance capital investment against potential gains in length of stay and complication avoidance. Consequently, commercial and clinical leaders must understand how device portfolios, service models, and training infrastructures align with procedural pathways to unlock operational benefits and sustainable clinical improvement.
How advances in robotics, visualization, consumables, and digital integration are collectively redefining procedural standards and value delivery in thoracic surgery
In recent years, several transformative shifts have redefined the landscape of minimally invasive thoracic surgery, and these developments continue to accelerate. First, the maturation of robotic assistance has broadened the scope of complex resections and precise dissection, making once challenging procedures more reproducible across varied institutional settings. Concurrently, the refinement of uniportal and multiport video-assisted approaches has improved instrument maneuverability and reduced incision burden, prompting institutions to revise procedural protocols and perioperative care pathways.
Second, visualization technologies have progressed from standard-definition optics to high-definition and stereoscopic systems that materially improve tissue differentiation. This enhancement in visual fidelity directly supports more conservative tissue handling and faster intraoperative decision making. Third, consumable design-such as advanced energy devices and purpose-engineered stapling systems-has evolved to prioritize hemostasis and seal integrity while simplifying user interaction in constrained thoracic anatomy. Finally, cross-cutting trends in digital integration, such as intraoperative imaging registration and tele-mentoring, are enabling distributed teams to share expertise and accelerate competency acquisition. Taken together, these shifts are creating new vectors for value-based care, where clinical outcomes, procedural efficiency, and patient experience are aligned with commercial and operational strategies.
An exploration of how recent tariff dynamics are reshaping sourcing strategies, procurement practices, and product life cycle decisions across the thoracic surgery ecosystem
Cumulative changes in trade policy affecting medical device flows into and out of the United States have created a new layer of commercial and operational complexity for suppliers and providers. Tariff adjustments and related trade measures have increased the need for manufacturers to reassess supply chain footprints, sourcing strategies, and inventory buffers in order to maintain consistent device availability for thoracic programs. As global supply networks respond, procurement teams have had to widen their vendor evaluations and consider nearshoring or regional distribution models to mitigate exposure to tariff volatility.
Moreover, tariff-driven cost pressures have stimulated renewed interest in product rationalization and lifecycle management, encouraging suppliers to emphasize modular designs and reusable components where clinically appropriate. From an operational perspective, clinicians and materials managers are increasingly collaborating to forecast demand for critical consumables tied to thoracic procedures, recognizing that uninterrupted access to energy devices, staplers, and visualization platforms is essential to maintain surgical cadence and quality of care. In parallel, regulatory and reimbursement stakeholders are scrutinizing how cost shifts interact with care pathways, prompting both manufacturers and provider groups to document clinical value propositions with greater rigor. Consequently, the influence of tariff dynamics is prompting strategic adjustments across procurement, manufacturing, and clinical practice to preserve access and maintain high standards of patient care.
Comprehensive segmentation insight tying procedure approaches, product portfolios, end-user profiles, system technologies, and clinical applications to operational and clinical decision levers
A nuanced segmentation lens is essential to understand the diversity of clinical workflows and product needs across minimally invasive thoracic surgery. When broken down by procedure type, distinctions among robotic assisted thoracoscopic surgery, uniportal VATS, and video assisted thoracoscopic surgery matter greatly for device selection, OR setup, and training priorities because each approach imposes different ergonomic and visualization requirements. Examining product categories reveals that energy devices, instruments, staplers and disposables, and visualization systems form the core technology stack; further granularity shows that energy options such as advanced bipolar, electrocautery, and ultrasonic approaches offer varied profiles for hemostasis and thermal spread, while instruments like dissectors, graspers, and scissors differ in tactile feedback and shaft articulation, impacting surgeon preference and institutional standardization.
End-user segmentation distinguishes ambulatory surgical centers from hospitals, and within hospital settings the contrast between community hospitals and tertiary care centers shapes purchasing thresholds, case mix, and training resources. Technology classifications spanning multiport systems, robotic systems, and single-port systems define procedural architectures and capital planning cycles. Finally, application-level framing into diagnostic and therapeutic use clarifies clinical intent and downstream workflow implications, since diagnostic procedures typically emphasize visualization and sampling efficiency whereas therapeutic interventions prioritize robust stapling solutions, energy control, and access to advanced instrumentation. In combination, these segmentation dimensions create a multidimensional decision framework that informs product development, clinical implementation plans, and commercialization tactics.
Regional dynamics and implementation patterns that determine how clinical practices, reimbursement systems, and supply chain realities influence thoracic surgery adoption across global regions
Geographic dynamics play a central role in the diffusion of minimally invasive thoracic surgery technologies and clinical practices, with regional differences influencing adoption timelines, procurement norms, and training infrastructures. In the Americas, a concentration of academic centers and integrated health systems often accelerates the introduction of robotics and advanced visualization, while private ambulatory surgical centers increasingly adopt targeted procedural capabilities to meet demand for shorter hospital stays. Across Europe, the Middle East and Africa, heterogeneous regulatory environments and variable payer models shape the cadence of uptake, with centers of excellence in major urban hubs driving education and cascading best practices to surrounding institutions. In the Asia-Pacific region, a diverse mix of high-volume tertiary centers and rapidly expanding surgical capacity fosters both innovation and price sensitivity, prompting manufacturers to tailor portfolio strategies and service models to local reimbursement and procurement realities.
In all regions, cross-border collaboration in training, clinical research, and technology transfer continues to narrow capability gaps. Moreover, regional supply chain considerations and regulatory pathways influence where manufacturers prioritize manufacturing investments and distribution partnerships. Taken together, regional insights underscore the importance of aligning commercial approaches with local clinical priorities, reimbursement structures, and operational constraints to successfully introduce and scale minimally invasive thoracic surgery solutions.
Company level strategies centered on integrated platforms, advanced consumables, visualization innovations, and training services that drive clinical adoption and commercial resilience
Companies operating in the minimally invasive thoracic surgery space are evolving along several complementary strategies to capture clinical relevance and commercial resilience. Leading device OEMs are prioritizing interoperability, delivering platforms and instruments that integrate visualization, energy, and stapling solutions to reduce intraoperative friction. Robotic system firms are optimizing workflow through streamlined docking, surgeon ergonomics, and instrument longevity, while consumable manufacturers are investing in features that enhance staple line integrity and energy device precision to minimize complication risks.
At the same time, imaging and visualization specialists are advancing high-definition optics and three-dimensional endoscopes to improve intraoperative decision making, and service providers are expanding training curricula and remote support offerings to accelerate surgeon proficiency. Strategic collaborations between small innovative firms and larger medical device companies are enabling faster clinical validation and scaled distribution. Additionally, firms are increasingly focusing on post-market data capture to substantiate clinical outcomes and support value-based procurement discussions. Collectively, these company-level trends suggest an industry that is converging around integrated solutions, enhanced clinical support, and evidence generation to meet the operational and clinical needs of contemporary thoracic programs.
High-impact, practical recommendations for manufacturers, providers, and procurement leaders to align clinical efficacy with operational efficiency and long-term strategic value
Industry leaders should adopt a series of targeted, actionable measures to capitalize on clinical advances and operational imperatives in minimally invasive thoracic surgery. First, prioritize partnerships that enable interoperability between visualization, energy, and stapling systems to reduce intraoperative complexity and procurement fragmentation. Second, invest in structured training programs and competency-based curricula that combine hands-on simulation with proctoring and remote mentorship to shorten learning curves and support wider adoption across community hospitals and ambulatory surgical centers. Third, reassess supply chain architectures with an emphasis on diversification and regional distribution to mitigate tariff exposure and ensure uninterrupted access to critical consumables.
Fourth, develop robust post-market evidence strategies that document clinical outcomes, resource utilization, and patient-reported measures to strengthen value conversations with payers and health systems. Fifth, refine product portfolios to offer modular and scalable solutions that align with the differentiated needs of tertiary centers versus community facilities, enabling tailored commercial models and pricing approaches. Sixth, deploy digital tools for inventory management and predictive demand forecasting to reduce stockouts and waste while enhancing OR throughput. By implementing these measures in a coordinated manner, organizations can better align clinical efficacy with operational efficiency and create defensible value propositions in a rapidly evolving therapeutic area.
A rigorous, transparent methodological framework combining primary clinical engagement, secondary technical review, and multi-source triangulation to validate insights and implications
The research underpinning this executive summary combined a multi-method approach designed to ensure validity, reliability, and relevance to decision makers. Primary engagement included structured interviews with thoracic surgeons, perioperative nursing leaders, procurement executives, and clinical educators to capture real-world insights on device performance, training bottlenecks, and adoption drivers. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory filings, device labeling, and manufacturer technical specifications to contextualize technological attributes and clinical indications. Data triangulation was employed to reconcile qualitative perspectives with documented device characteristics and procedural guidelines, producing a balanced interpretation of industry dynamics.
Analytical techniques included thematic synthesis of interview data, comparative product feature mapping, and scenario analysis to assess the implications of supply chain and policy shifts. Quality assurance measures comprised cross-validation by clinical advisors and iterative review cycles with industry subject-matter experts to identify blind spots and validate conclusions. Limitations were acknowledged, including variability in institutional practices and evolving regulatory landscapes that may alter adoption dynamics over time. Nonetheless, the methodology prioritized transparency and replicability to ensure that findings are actionable for commercial, clinical, and policy stakeholders.
A concise, strategic conclusion that synthesizes technological progress, supply chain realities, and segmentation insights to guide informed clinical and commercial decisions
In summary, minimally invasive thoracic surgery stands at a pivotal juncture where technological maturity, clinical capability, and supply chain realities converge to create new opportunities and responsibilities for stakeholders. The integration of advanced robotics, refined instrumentation, and superior visualization is reshaping procedural norms, while tariff and procurement dynamics are prompting pragmatic adjustments to sourcing and product design. Segmented clinical pathways and regional variations necessitate differentiated commercial strategies that align product portfolios with end-user capacity and application intent. Moreover, company strategies that emphasize interoperability, training, and evidence generation are most likely to achieve sustained clinical relevance and organizational value.
Looking ahead, stakeholders who proactively align their product development, supply chain, and clinical education efforts will be best positioned to support improved patient outcomes and operational efficiency. By balancing innovation with pragmatic implementation planning and robust post-market evidence collection, manufacturers and providers can navigate uncertainty while advancing the standard of care in thoracic surgery.
Note: PDF & Excel + Online Access - 1 Year
A forward-looking introduction that frames clinical evolution, stakeholder incentives, and the strategic convergence shaping minimally invasive thoracic surgery adoption
The evolution of thoracic surgery toward less invasive approaches has entered a stage where clinical promise and commercial momentum intersect. Advances in instrumentation, imaging, and robotic assistance have collectively shifted procedural paradigms, enabling surgeons to reduce patient trauma and expedite recovery while preserving or improving diagnostic and therapeutic effectiveness. This shift is not solely technical; it reflects a broad, multipronged transformation driven by payers, patients, and providers who increasingly prioritize outcomes, throughput, and predictable perioperative pathways.
Clinicians now operate within an ecosystem that demands interoperability between devices, streamlined disposable management, and consistent visualization quality. As a result, technology adoption decisions are informed by procedure type, device ergonomics, and institutional capacity to support next-generation tools. Meanwhile, health systems are recalibrating resource allocation to balance capital investment against potential gains in length of stay and complication avoidance. Consequently, commercial and clinical leaders must understand how device portfolios, service models, and training infrastructures align with procedural pathways to unlock operational benefits and sustainable clinical improvement.
How advances in robotics, visualization, consumables, and digital integration are collectively redefining procedural standards and value delivery in thoracic surgery
In recent years, several transformative shifts have redefined the landscape of minimally invasive thoracic surgery, and these developments continue to accelerate. First, the maturation of robotic assistance has broadened the scope of complex resections and precise dissection, making once challenging procedures more reproducible across varied institutional settings. Concurrently, the refinement of uniportal and multiport video-assisted approaches has improved instrument maneuverability and reduced incision burden, prompting institutions to revise procedural protocols and perioperative care pathways.
Second, visualization technologies have progressed from standard-definition optics to high-definition and stereoscopic systems that materially improve tissue differentiation. This enhancement in visual fidelity directly supports more conservative tissue handling and faster intraoperative decision making. Third, consumable design-such as advanced energy devices and purpose-engineered stapling systems-has evolved to prioritize hemostasis and seal integrity while simplifying user interaction in constrained thoracic anatomy. Finally, cross-cutting trends in digital integration, such as intraoperative imaging registration and tele-mentoring, are enabling distributed teams to share expertise and accelerate competency acquisition. Taken together, these shifts are creating new vectors for value-based care, where clinical outcomes, procedural efficiency, and patient experience are aligned with commercial and operational strategies.
An exploration of how recent tariff dynamics are reshaping sourcing strategies, procurement practices, and product life cycle decisions across the thoracic surgery ecosystem
Cumulative changes in trade policy affecting medical device flows into and out of the United States have created a new layer of commercial and operational complexity for suppliers and providers. Tariff adjustments and related trade measures have increased the need for manufacturers to reassess supply chain footprints, sourcing strategies, and inventory buffers in order to maintain consistent device availability for thoracic programs. As global supply networks respond, procurement teams have had to widen their vendor evaluations and consider nearshoring or regional distribution models to mitigate exposure to tariff volatility.
Moreover, tariff-driven cost pressures have stimulated renewed interest in product rationalization and lifecycle management, encouraging suppliers to emphasize modular designs and reusable components where clinically appropriate. From an operational perspective, clinicians and materials managers are increasingly collaborating to forecast demand for critical consumables tied to thoracic procedures, recognizing that uninterrupted access to energy devices, staplers, and visualization platforms is essential to maintain surgical cadence and quality of care. In parallel, regulatory and reimbursement stakeholders are scrutinizing how cost shifts interact with care pathways, prompting both manufacturers and provider groups to document clinical value propositions with greater rigor. Consequently, the influence of tariff dynamics is prompting strategic adjustments across procurement, manufacturing, and clinical practice to preserve access and maintain high standards of patient care.
Comprehensive segmentation insight tying procedure approaches, product portfolios, end-user profiles, system technologies, and clinical applications to operational and clinical decision levers
A nuanced segmentation lens is essential to understand the diversity of clinical workflows and product needs across minimally invasive thoracic surgery. When broken down by procedure type, distinctions among robotic assisted thoracoscopic surgery, uniportal VATS, and video assisted thoracoscopic surgery matter greatly for device selection, OR setup, and training priorities because each approach imposes different ergonomic and visualization requirements. Examining product categories reveals that energy devices, instruments, staplers and disposables, and visualization systems form the core technology stack; further granularity shows that energy options such as advanced bipolar, electrocautery, and ultrasonic approaches offer varied profiles for hemostasis and thermal spread, while instruments like dissectors, graspers, and scissors differ in tactile feedback and shaft articulation, impacting surgeon preference and institutional standardization.
End-user segmentation distinguishes ambulatory surgical centers from hospitals, and within hospital settings the contrast between community hospitals and tertiary care centers shapes purchasing thresholds, case mix, and training resources. Technology classifications spanning multiport systems, robotic systems, and single-port systems define procedural architectures and capital planning cycles. Finally, application-level framing into diagnostic and therapeutic use clarifies clinical intent and downstream workflow implications, since diagnostic procedures typically emphasize visualization and sampling efficiency whereas therapeutic interventions prioritize robust stapling solutions, energy control, and access to advanced instrumentation. In combination, these segmentation dimensions create a multidimensional decision framework that informs product development, clinical implementation plans, and commercialization tactics.
Regional dynamics and implementation patterns that determine how clinical practices, reimbursement systems, and supply chain realities influence thoracic surgery adoption across global regions
Geographic dynamics play a central role in the diffusion of minimally invasive thoracic surgery technologies and clinical practices, with regional differences influencing adoption timelines, procurement norms, and training infrastructures. In the Americas, a concentration of academic centers and integrated health systems often accelerates the introduction of robotics and advanced visualization, while private ambulatory surgical centers increasingly adopt targeted procedural capabilities to meet demand for shorter hospital stays. Across Europe, the Middle East and Africa, heterogeneous regulatory environments and variable payer models shape the cadence of uptake, with centers of excellence in major urban hubs driving education and cascading best practices to surrounding institutions. In the Asia-Pacific region, a diverse mix of high-volume tertiary centers and rapidly expanding surgical capacity fosters both innovation and price sensitivity, prompting manufacturers to tailor portfolio strategies and service models to local reimbursement and procurement realities.
In all regions, cross-border collaboration in training, clinical research, and technology transfer continues to narrow capability gaps. Moreover, regional supply chain considerations and regulatory pathways influence where manufacturers prioritize manufacturing investments and distribution partnerships. Taken together, regional insights underscore the importance of aligning commercial approaches with local clinical priorities, reimbursement structures, and operational constraints to successfully introduce and scale minimally invasive thoracic surgery solutions.
Company level strategies centered on integrated platforms, advanced consumables, visualization innovations, and training services that drive clinical adoption and commercial resilience
Companies operating in the minimally invasive thoracic surgery space are evolving along several complementary strategies to capture clinical relevance and commercial resilience. Leading device OEMs are prioritizing interoperability, delivering platforms and instruments that integrate visualization, energy, and stapling solutions to reduce intraoperative friction. Robotic system firms are optimizing workflow through streamlined docking, surgeon ergonomics, and instrument longevity, while consumable manufacturers are investing in features that enhance staple line integrity and energy device precision to minimize complication risks.
At the same time, imaging and visualization specialists are advancing high-definition optics and three-dimensional endoscopes to improve intraoperative decision making, and service providers are expanding training curricula and remote support offerings to accelerate surgeon proficiency. Strategic collaborations between small innovative firms and larger medical device companies are enabling faster clinical validation and scaled distribution. Additionally, firms are increasingly focusing on post-market data capture to substantiate clinical outcomes and support value-based procurement discussions. Collectively, these company-level trends suggest an industry that is converging around integrated solutions, enhanced clinical support, and evidence generation to meet the operational and clinical needs of contemporary thoracic programs.
High-impact, practical recommendations for manufacturers, providers, and procurement leaders to align clinical efficacy with operational efficiency and long-term strategic value
Industry leaders should adopt a series of targeted, actionable measures to capitalize on clinical advances and operational imperatives in minimally invasive thoracic surgery. First, prioritize partnerships that enable interoperability between visualization, energy, and stapling systems to reduce intraoperative complexity and procurement fragmentation. Second, invest in structured training programs and competency-based curricula that combine hands-on simulation with proctoring and remote mentorship to shorten learning curves and support wider adoption across community hospitals and ambulatory surgical centers. Third, reassess supply chain architectures with an emphasis on diversification and regional distribution to mitigate tariff exposure and ensure uninterrupted access to critical consumables.
Fourth, develop robust post-market evidence strategies that document clinical outcomes, resource utilization, and patient-reported measures to strengthen value conversations with payers and health systems. Fifth, refine product portfolios to offer modular and scalable solutions that align with the differentiated needs of tertiary centers versus community facilities, enabling tailored commercial models and pricing approaches. Sixth, deploy digital tools for inventory management and predictive demand forecasting to reduce stockouts and waste while enhancing OR throughput. By implementing these measures in a coordinated manner, organizations can better align clinical efficacy with operational efficiency and create defensible value propositions in a rapidly evolving therapeutic area.
A rigorous, transparent methodological framework combining primary clinical engagement, secondary technical review, and multi-source triangulation to validate insights and implications
The research underpinning this executive summary combined a multi-method approach designed to ensure validity, reliability, and relevance to decision makers. Primary engagement included structured interviews with thoracic surgeons, perioperative nursing leaders, procurement executives, and clinical educators to capture real-world insights on device performance, training bottlenecks, and adoption drivers. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory filings, device labeling, and manufacturer technical specifications to contextualize technological attributes and clinical indications. Data triangulation was employed to reconcile qualitative perspectives with documented device characteristics and procedural guidelines, producing a balanced interpretation of industry dynamics.
Analytical techniques included thematic synthesis of interview data, comparative product feature mapping, and scenario analysis to assess the implications of supply chain and policy shifts. Quality assurance measures comprised cross-validation by clinical advisors and iterative review cycles with industry subject-matter experts to identify blind spots and validate conclusions. Limitations were acknowledged, including variability in institutional practices and evolving regulatory landscapes that may alter adoption dynamics over time. Nonetheless, the methodology prioritized transparency and replicability to ensure that findings are actionable for commercial, clinical, and policy stakeholders.
A concise, strategic conclusion that synthesizes technological progress, supply chain realities, and segmentation insights to guide informed clinical and commercial decisions
In summary, minimally invasive thoracic surgery stands at a pivotal juncture where technological maturity, clinical capability, and supply chain realities converge to create new opportunities and responsibilities for stakeholders. The integration of advanced robotics, refined instrumentation, and superior visualization is reshaping procedural norms, while tariff and procurement dynamics are prompting pragmatic adjustments to sourcing and product design. Segmented clinical pathways and regional variations necessitate differentiated commercial strategies that align product portfolios with end-user capacity and application intent. Moreover, company strategies that emphasize interoperability, training, and evidence generation are most likely to achieve sustained clinical relevance and organizational value.
Looking ahead, stakeholders who proactively align their product development, supply chain, and clinical education efforts will be best positioned to support improved patient outcomes and operational efficiency. By balancing innovation with pragmatic implementation planning and robust post-market evidence collection, manufacturers and providers can navigate uncertainty while advancing the standard of care in thoracic surgery.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
183 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Expanding adoption of uniportal video-assisted thoracic surgery techniques to reduce patient recovery time
- 5.2. Integration of artificial intelligence-driven imaging guidance for precise minimally invasive lung tumor resections
- 5.3. Emergence of augmented reality navigation systems enhancing surgeon visualization in thoracic procedures
- 5.4. Development of flexible endoscopic instruments enabling access to hard-to-reach pulmonary nodules with minimal trauma
- 5.5. Growth of outpatient and same-day discharge protocols in minimally invasive thoracic surgery settings
- 5.6. Advancements in energy-based sealing devices reducing intraoperative bleeding during thoracoscopic interventions
- 5.7. Increasing investments in remote proctoring platforms for virtual surgeon training and skill assessment in MIS
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Minimally Invasive Thoracic Surgery Market, by Procedure Type
- 8.1. Lung Resection Procedures
- 8.1.1. Lobectomy
- 8.1.2. Segmentectomy
- 8.1.3. Wedge Resection
- 8.1.4. Pneumonectomy
- 8.1.5. Lung Volume Reduction Surgery
- 8.2. Esophageal Procedures
- 8.2.1. Esophagectomy
- 8.2.2. Anti-Reflux Surgery
- 8.2.3. Myotomy
- 8.3. Mediastinal Procedures
- 8.3.1. Thymectomy
- 8.3.2. Mediastinal Tumor Resection
- 8.3.3. Lymph Node Dissection
- 8.4. Pleural Procedures
- 8.4.1. Pleurodesis
- 8.4.2. Decortication
- 8.4.3. Bullectomy
- 8.4.4. Pleural Biopsy
- 8.5. Sympathetic Procedures
- 9. Minimally Invasive Thoracic Surgery Market, by Product Type
- 9.1. Surgical Systems
- 9.1.1. Thoracoscopic Video Systems
- 9.1.2. Robotic Surgical Platforms
- 9.2. Surgical Instruments
- 9.2.1. Endoscopic Hand Instruments
- 9.2.2. Endoscopic Stapling Devices
- 9.2.3. Energy Devices
- 9.2.3.1. Electrosurgical Devices
- 9.2.3.2. Ultrasonic Devices
- 9.2.3.3. Advanced Bipolar Devices
- 9.2.4. Suction-Irrigation Devices
- 9.3. Access Devices
- 9.3.1. Trocars & Ports
- 9.3.2. Access Needles
- 9.3.3. Wound Protectors
- 9.4. Closure & Hemostasis Products
- 9.4.1. Sutures & Clips
- 9.4.2. Staple Line Reinforcement Materials
- 9.4.3. Sealants & Hemostatic Agents
- 9.5. Imaging & Navigation
- 9.5.1. Intraoperative Imaging Systems
- 9.5.2. Fluorescence Imaging Systems
- 9.5.3. Navigation & Mapping Systems
- 10. Minimally Invasive Thoracic Surgery Market, by Indication
- 10.1. Malignant Thoracic Diseases
- 10.1.1. Primary Lung Cancer
- 10.1.1.1. Early-Stage Non-Small Cell Lung Cancer
- 10.1.1.2. Locally Advanced Non-Small Cell Lung Cancer
- 10.1.2. Metastatic Lung Lesions
- 10.1.3. Esophageal Cancer
- 10.1.4. Mediastinal Malignancies
- 10.2. Benign Thoracic Diseases
- 10.2.1. Pneumothorax
- 10.2.2. Empyema
- 10.2.3. Benign Esophageal Disorders
- 10.2.3.1. Gastroesophageal Reflux Disease
- 10.2.3.2. Achalasia
- 10.2.4. Mediastinal Cysts And Benign Tumors
- 10.2.5. Hyperhidrosis
- 10.2.6. Benign Pulmonary Nodules
- 11. Minimally Invasive Thoracic Surgery Market, by End User
- 11.1. Hospitals
- 11.1.1. Tertiary Care Hospitals
- 11.1.2. Community Hospitals
- 11.1.3. Specialty Thoracic Centers
- 11.2. Ambulatory Surgical Centers
- 11.3. Specialty Clinics
- 11.4. Academic And Research Institutes
- 12. Minimally Invasive Thoracic Surgery Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Minimally Invasive Thoracic Surgery Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Minimally Invasive Thoracic Surgery Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. B. Braun Melsungen AG
- 15.3.2. Becton, Dickinson and Company
- 15.3.3. Boston Scientific Corporation
- 15.3.4. Cardio Medical GmbH
- 15.3.5. CONMED Corporation
- 15.3.6. Cook Medical LLC
- 15.3.7. Dextera Surgical, Inc.
- 15.3.8. Fujifilm Holdings Corporation
- 15.3.9. GE HealthCare, Inc.
- 15.3.10. Grena Ltd.
- 15.3.11. Intuitive Surgical, Inc.
- 15.3.12. Johnson & Johnson
- 15.3.13. KARL STORZ SE & Co. KG
- 15.3.14. Koninklijke Philips N.V.
- 15.3.15. LivaNova plc
- 15.3.16. Medela Healthcare
- 15.3.17. Medtronic plc
- 15.3.18. Merit Medical Systems, Inc.
- 15.3.19. Olympus Corporation
- 15.3.20. Sklar Surgical Instruments
- 15.3.21. Smith & Nephew plc
- 15.3.22. Stryker Corporation
- 15.3.23. Teleflex Incorporated
- 15.3.24. Terumo Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
